Inextron Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the plate, announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO.

SIOUX CENTER, Iowa, July 8, 2019

National Center for Advancing Translational Sciences supports generation, characterization of a MiniSwine model of Sickle Cell Disease, to support life changing research for patients.

Dalmose, Denmark, 26 November 2018

Ellegaard Göttingen Minipigs A/S, today announced the signing of a license and commercialization agreement with Exemplar Genetics to develop and commercialize genetically modified Göttingen Minipigs models of human disease on a target-by-target basis. Göttingen Minipigs are a small, docile, microbiologically and genetically well-defined large animal model recognized by the global biomedical research community and regulatory authorities, making Göttingen Minipigs the genetics of choice for preclinical studies.

Original research article published on April 18, 2018 in Circulation.

DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.032184 Circulation. 2018;CIRCULATIONAHA.117.032184

Download PDF from Circulation here

July 10–13, 2017 - BCVS Scientific Sessions 2017
Exemplar Genetics presented an Oral Abstract at the BCVS Scientific Sessions in Portland, Oregon titled "A MiniSwine Genetic Model of Hypertrophic Cardiomyopathy". Review the abstract in its entirety here
Wednesday, March 22, 2017 10:45 AM
John Swart, founder and president of Exemplar Genetics, won this year's Cultivation Corridor Iowa Biotech Leadership Award, which recognizes leadership, innovation, advocacy and commitment in the biotech industry. Swart founded the company in 2008 in Sioux Center to develop specialized miniature swine models that exhibit human disease states to help test whether medications and devices work. Former Monsanto executive Ted Crosbie, who died last year, also was recognized for his contributions to the industry.
Sioux Center, IA - September 13, 2016

Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced two publication in the current issue of the Journal of Clinical Investigation (JCI) demonstrating the potential of ExeGen® CFTR MiniSwine research models to help define and develop effective gene therapies for cystic fibrosis.